Table 3A

Continued

  Taioli et al. 1995 (59)All cases0.091Ile/Val het1.10.3–4.0No Val/Val homozygous cases
  Ishibe et al. 1998 (41)All casesNSVal carrier0.880.58–1.33Multivariate-adjusted OR
  Bailey et al. 1998 (23)All Caucasian0.037Ile/Val het1.260.57–2.78No Val/Val homozygotes
CYP1A1 3′ UTR T6235C
  Taioli et al. 1995 (59)Caucasian0.115TC het1.70.6–4.9
African-American0.218TC het2.40.7–7.7
CC hom 9.7 2.0–47.9
  Ishibe et al. 1998 (41)All casesNSC carrier1.050.74–1.50Multivariate-adjusted OR
  Bailey et al. 1998 (23)Caucasian0.096TC het1.490.81–2.74
CC hom0.840.22–3.19
African-American0.247TC het0.510.23–1.13
CC hom0.520.08–3.32
CYP1A1 3′ UTR T5639C
  Taioli et al. 1995 (59)African American0.081TC het1.20.3–5.3No CC homozygotes
  Bailey et al. 1998 (23)African-American0.119TC het0.750.31–1.83No CC homozygotes
CYP1A1 Thr461Asp
  Bailey et al. 1998 (23)Caucasian0.043Thr/Asp het0.810.34–1.94
Asp/Asp hom0.970.06–15.71
CYP2D6 poor metabolizer
  Buchert et al. 1993 (24)All cases0.061Poor metabolizer1.180.42–3.45Tested for A, B, and D alleles
Pre-men0.121.540.35–7.66Poor metabolizer = low-activity allele homozygote or compound heterozygote
Post-men0.610.12–4.11
  Smith et al. 1992 (57)All cases0.043Poor metabolizer0.900.47–1.71Tested for A, B, and D alleles
  Huober et al. 1991 (36)All cases0.073dPoor metabolizer1.730.66–4.63Phenotype study
  Ladona et al. 1996 (46)All cases0.040dPoor metabolizer0.660.16–2.69Tested for A, B, and C alleles
  Pontin et al. 1998 (53)All cases0.062dPoor metabolizer1.700.63–4.67Phenotype study
  Ladero et al. 1991 (45)All cases0.052dPoor metabolizer2.090.97–4.48Phenotype study
CYP2E1
  Shields et al. 1996 (54)Pre-men0.09C carrier1.040.48–2.24
Post-men0.07C carrier1.010.55–1.84
GSTM1 deletion
  Zhong et al. 1993 (64)All cases0.418eNull1.270.87–1.87
  Ambrosone et al. 1995 (20)Post-men cases0.502eNull1.100.73–1.64Adjusted for age, age at menarche/first pregnancy/menopause, BMI, and family history
  Kelsey et al. 1997 (44)Prevalent cases0.51Null1.300.91–1.86Null cases associated with improved survival
Incident cases0.48Null1.080.74–1.57
  Bailey et al. 1998 (23)Caucasian0.383eNull0.770.50–1.20
African-American0.407e0.750.35–1.58
  Helzlsouer et al. 1998 (34)All cases0.464eNull 2.10 1.22–3.64 Adjusted for age and menopausal status
Pre-men cases1.00.28–3.45
Post-men cases 2.50 1.34–4.65
  Charrier et al. 1999 (26)All cases0.51Null1.190.90–1.59
<50 years0.970.69–1.35
≥50 years 1.99 1.19–3.32
GSTT1 deletion
  Helzlsouer et al. 1998 (34)All0.214eNull1.500.76–2.95Adjusted for age and menopausal status
Pre-men1.500.42–5.32
Post-men1.500.67–3.34
  Bailey et al. 1998 (23)Caucasian0.272eNull1.080.66–1.75
African-American0.288e0.630.27–1.47
GSTP1 Ile105Val
  Helzlsouer et al. 1998 (34)All0.29Ile/Val het1.480.81–2.73Adjusted for age and menopausal status
Pre-men1.980.44–8.81
Post-men1.330.68–2.61
AllVal/Val hom1.970.77–5.02
Pre-men0.540.04–6.67
Post-men2.710.91–8.03
  Harries et al. 1997 (33)All0.28Ile/Val het1.530.83–2.84
Val/Val hom1.580.49–5.06
NAT1 A1088T
  Millikan et al. 1998 (50)Pre-men cases0.47T carrier1.20.8–1.8
Post-men cases0.46T carrier1.00.7–1.5
  Zheng et al. 1999 (63)0.17T carrier1.180.77–1.81